New Insights on Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis: What a 201-Participant Study Found

To evaluate the long-term safety and real-world benefits of add-on cannabidiol (CBD) in patients with seizures associated with tuberous sclerosis complex (TSC) in the open-label extension (OLE) of the randomized, compared against a dummy pill (placebo) phase 3 trial GWPCARE6 (NCT02544763). When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

To find out, researchers writing in Epilepsia conducted a phase iii randomized trial evaluating 201 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

Of 201 patients who completed the randomized phase, 199 (99%) entered the OLE. Mean age was 13 years (range, 1-57). At the time of analysis, 5% of patients had completed treatment, 20% had withdrawn, and 75% were ongoing. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.